The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Merck entered a $510 million collaboration with Protillion Therapeutics to leverage AI for drug discovery. Following this, the company announced that its Phase 3 ATLAS-UC study of tulisokibart successfully met its primary and key secondary endpoints. The anti-TL1A antibody demonstrated positive results in late-stage trials for patients suffering from ulcerative colitis.